Universal Clinical Codes & Terminology Search

Optical coherence tomography of breast surgical cavity; interpretation and report real-time or referred

Human papilloma virus (HPV) high-risk types (ie 16 18 31 33 45 52 and 58) qualitative mRNA expression of E6/E7 by quantitative polymerase chain reaction (qPCR)

Gastrointestinal tract imaging intraluminal (eg capsule endoscopy) colon with interpretation and report

APOL1 (apolipoprotein L1) (eg chronic kidney disease) risk variants (G1 G2)

Insertion of drug-eluting implant (including punctal dilation and implant removal when performed) into lacrimal canaliculus each

Oncology (oropharyngeal) evaluation of 17 DNA biomarkers using droplet digital PCR (ddPCR) cell-free DNA algorithm reported as a prognostic risk score for cancer recurrence

Cryopreservation; immature oocyte(s)

Oncology (melanoma) artificial intelligence (AI)-enabled quantitative mass spectrometry analysis of 142 unique pairs of glycopeptide and product fragments plasma prognostic and predictive algorithm reported as likely unlikely or uncertain benefit from immunotherapy agents

Bioelectrical impedance analysis whole body composition assessment with interpretation and report

Neurology (mild cognitive impairment) analysis of B-amyloid 1-42 and 1-40 chemiluminescence enzyme immunoassay cerebral spinal fluid reported as positive likely positive or negative

Behavior identification assessment by the physician or other qualified health care professional face-to-face with patient and caregiver(s) includes administration of standardized and non-standardized tests detailed behavioral history patient observation and caregiver interview interpretation of test results discussion of findings and recommendations with the primary guardian(s)/caregiver(s) and preparation of report

Oncology (prostate cancer) analysis of all prostate-specific antigen (PSA) structural isoforms by phase separation and immunoassay plasma algorithm reports risk of cancer

Observational behavioral follow-up assessment includes physician or other qualified health care professional direction with interpretation and report administered by one technician; first 30 minutes of technician time face-to-face with the patient

Oncology (lung) enzyme-linked immunosorbent assay (ELISA) of 7 autoantibodies (p53 NY-ESO-1 CAGE GBU4-5 SOX2 MAGE A4 and HuD) plasma algorithm reported as a categorical result for risk of malignancy

Observational behavioral follow-up assessment includes physician or other qualified health care professional direction with interpretation and report administered by one technician; each additional 30 minutes of technician time face-to-face with the patient (List separately in addition to code for primary service)

Neurofilament light chain digital immunoassay plasma quantitative

Exposure behavioral follow-up assessment includes physician or other qualified health care professional direction with interpretation and report administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time face-to-face with the patient

Oncology (papillary thyroid cancer) gene-expression profiling via targeted hybrid capture-enrichment RNA sequencing of 82 content genes and 10 housekeeping genes fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue algorithm reported as one of three molecular subtypes

Exposure behavioral follow-up assessment includes physician or other qualified health care professional direction with interpretation and report administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time face-to-face with the patient (List separately in addition to code for primary procedure)

Oncology (urothelial) mRNA gene-expression profiling by real-time quantitative PCR of 5 genes (MDK HOXA13 CDC2 [CDK1] IGFBP5 and CXCR2) utilizing urine algorithm incorporates age sex smoking history and macrohematuria frequency reported as a risk score for having urothelial carcinoma